Our findings, as summarized in Figure 11, support the conclusion that DHA+DEX cotreatment synergistically quells LPS-induced changes in transcription and regulatory factor activities, markedly attenuating expression of IFN-stimulated and proinflammatory genes that contribute to SLE pathogenesis. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.